Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

Lung Cancer

Volumn 41, Issue 1, 2003, Pages 107-111

  Skarlos, Dimosthenis Vasilios ^a,i   Dimopoulos, Athanassios Meletios ^b   Kosmidis, Paraskevas ^c   Papakostas, Pavlos ^d   Pavlidis, Nicholas ^e   Bacoyiannis, Charalambos ^c   Kiamouris, Christos ^b   Klouvas, Georgios ^a   Gogas, Helen ^f   Fountzilas, George ^g   Samantas, Epaminondas ^h  

^a Henry Dynan Hospital   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

^d Ippokration Hospital Thessaloniki   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f LAIKO GENERAL HOSPITAL   (Greece)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Docetaxel; Extensive small cell lung cancer; Gemcitabine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; MALE; ONCOLOGY; ORGANIZATION; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SMOKING; TOXICITY; TREATMENT OUTCOME;

EID: 0038798479     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00154-5     Document Type: Article

References (13)

1. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer. Perceptible progress. J. Clin. Oncol. 17:1999;1794-1801.
2. Ettinger D.S. New drugs for chemotherapy-naïve patients with extensive-disease small cell lung cancer. Semin. Oncol. 28:(Suppl. 4):2001;27-29.
3. Milber A.B., Hoogstraten B., Winkler A. Reporting results of cancer treatment. Cancer. 47:1991;207-214.
4. Machin D., Campel M., Fayers P., Pinol A. Sample size tables for clinical studies. 1999;254-286 Blackwell Science.
5. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
6. Lentner C. Geigy scientific tables. 1982;89-102 Ciba-Geigy Ltd.
7. Hesketh P.J., Growley J.J., Burris H.A., et al. Evaluation of Docetaxel in previously untreated extensive small cell lung cancer. A Southwest Oncology Group phase II trial. Cancer J. Sci. Am. 5:1999;237-241.
8. Smyth J.F., Smith I.E., Sessa C., et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORT. Eur. J. Cancer. 8:1994;1058.
9. Van der Lee I., Smitt E.F., Van Putten J.W.G., et al. Singe agent gemcitabine in patients with resistant small cell lung cancer. Ann. Oncol. 12:2001;557-561.
10. Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 5:1994;283-285.
11. Vansteenkiste J., Catzemeir V., Manegold C., et al. Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-center phase II study. Ann. Oncol. 12:2001;835-840.
12. Earle C.C., Stewart D.J., Cormier Y., et al. A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer (SCLC). Lung Cancer. 22:1998;235-241.
13. De Marinis F., Cortesi E., Paoluzzil L., et al. Cisplatin (P), etoposide (E) and gemcitabine (G) in untreated patients with small cell lung cancer (SCLC): preliminary results of a multi-institutional phase II trial of GOL (Oncological Group of Lazio). Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19:2000;A2062.